Jefferies Maintains a Buy on Taysha Gene Therapies (TSHA) With an $8 PT

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. In a report released on June 11, Maury Raycroft from Jefferies maintained a Buy rating on Taysha Gene Therapies, Inc. (NASDAQ:TSHA) with a price target of $8.00.

The analyst based the rating on the company’s promising potential, stating that its Rett gene therapy program is exhibiting notable progress. Updated clinical data suggests continuous patient benefits over time, especially in the case of high-dose treatments.

Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) the Best Bet in Gene Therapy Industry?

A laboratory technician preparing a gene therapy sample in a sterile environment.

Raycroft stated that although they are conservatively evaluated, the analysis of milestone gains points towards significant improvements in patient outcomes. Another factor supporting the Buy rating for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is the deep reduction in the R-MBA rating scale, which the analyst considers a positive surprise reflecting the effect of the therapy on a granular and well-developed scale.

Caregivers are also showing considerable interest in taking part in gene therapy trials, which, according to Raycroft, supports the potential for quick enrollment in pivotal studies.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company that develops and commercializes adeno-associated viruses (AAV) based gene therapies to treat monogenic diseases of the central nervous system. The company is also involved in the development of multiple gene therapy platforms, including AAV9 Discovery, Novel Capsid, and AAV Redosing.

While we acknowledge the potential of TSHA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.